Why Is Hemgenix So Hard to Find? [Explained for 2026]

If you or someone you love has hemophilia B and has been trying to access Hemgenix, you may have recently received troubling news: as of March 2026, CSL Behring announced a temporary global stockout of Hemgenix (etranacogene dezaparvovec-drlb). That announcement has understandably raised urgent questions for patients who have been waiting months — sometimes longer — to receive this life-changing gene therapy.

Even before the 2026 stockout, Hemgenix was never a drug you could simply call your local pharmacy to order. Here is a thorough explanation of why Hemgenix is so hard to find — and what you can do about it.

What Is Hemgenix and Why Is It Different From Most Medications?

Hemgenix is not your typical prescription drug. It is a one-time gene therapy approved by the FDA on November 22, 2022, making it the first-ever gene therapy for hemophilia B. It works by delivering a working copy of the Factor IX gene directly to liver cells using an adeno-associated virus serotype 5 (AAV5) vector. Once administered, your liver begins producing its own Factor IX — the clotting protein that people with hemophilia B are born without.

Hemgenix is dosed based on patient body weight at 2 × 10¹³ genome copies per kilogram (2 mL/kg), meaning each patient's kit is individually prepared and weight-specific. For a patient weighing 126–130 kg, the Hemgenix kit contains the exact number of vials needed for that weight range. This individualized, patient-specific manufacturing makes it fundamentally different from mass-produced pills or even standard infusion drugs.

At approximately $3.5 million per one-time dose, Hemgenix holds the record as one of the most expensive medicines in the United States. That price reflects the extraordinary complexity of manufacturing gene therapies at clinical-grade quality — and it is a major reason why availability is so tightly controlled.

The 2026 Hemgenix Global Stockout: What We Know

In March 2026, CSL Behring issued a formal letter to the hemophilia B community disclosing a temporary global stockout of Hemgenix. The company was clear that this situation is not related to the safety or effectiveness of the drug. Rather, it reflects the extraordinary complexity of manufacturing gene therapies and CSL Behring's commitment to adhering to the highest regulatory and quality standards.

What this means practically: patients who had been planning to receive Hemgenix in 2026, including those whose insurance approvals were in progress, may face treatment delays. CSL Behring said it is working with regulatory authorities on strategies to ensure stable ongoing supply.

Why Gene Therapy Manufacturing Is So Difficult

Gene therapy manufacturing is far more complex than conventional pharmaceutical production. Here are the key reasons:

Viral vector production is highly specialized. Growing AAV5 vectors to clinical scale requires bioreactors, cleanrooms, and extensive quality testing. Even small deviations can render an entire batch unusable.

Each kit is patient-specific. Because dosing is weight-based (2 mL/kg), Hemgenix is not mass-produced as standard unit doses. Patient-specific kits (like the 126–130 kg kit) must be prepared and verified for each individual patient.

Small patient population limits production volume. Hemophilia B affects about 1 in 40,000 people. Low production volume means manufacturers have less manufacturing runway to buffer against disruptions.

Regulatory oversight is intense. Gene therapies face rigorous FDA and EMA batch-release testing before any vial can be shipped. This adds time and creates potential bottlenecks.

Hemgenix Is Only Available at Certified Hemophilia Treatment Centers

Even when supply is normal, Hemgenix is not available at retail pharmacies. It is a limited-distribution drug that can only be administered at certified hemophilia treatment centers (HTCs) or specialized infusion facilities. These centers have the trained staff, emergency equipment, and monitoring protocols required for safe administration — including the ability to manage infusion-related reactions and monitor liver enzymes in the weeks following infusion.

Not every city or region has a qualified center. Patients sometimes need to travel significant distances for treatment. This geographic constraint adds another layer to the findability challenge.

Insurance and Prior Authorization Delays

Before a patient can even schedule their Hemgenix infusion, a complex insurance prior authorization process must be completed. Insurers typically require:

Confirmation of hemophilia B diagnosis with documented Factor IX activity levels

Negative Factor IX inhibitor test results (with potential retest if positive)

Documentation of current Factor IX prophylaxis or qualifying bleeding history

Baseline liver function tests and liver ultrasound

AAV5 neutralizing antibody test (provided and covered by CSL Behring)

This process typically takes 2–4 weeks but can extend longer if documentation is incomplete or if the insurer requests additional reviews. During the 2026 stockout, even patients with completed authorizations may face additional waits.

What Should Patients Do Right Now?

If you have been waiting for Hemgenix or your treatment has been delayed by the 2026 stockout, here are practical steps:

Stay in contact with your hemophilia treatment center. HTCs are receiving direct communications from CSL Behring and will have the most current information on restocking timelines for your region.

Enroll in HEMGENIX Connect. CSL Behring's HEMGENIX Connect program (1-833-436-0021, M–F 8AM–8PM ET) can connect you with a Case Manager who provides insurance support, financial assistance, and treatment coordination.

Continue Factor IX prophylaxis. Do not stop your current Factor IX prophylaxis regimen while waiting. Work with your hematologist to ensure you are adequately protected.

Discuss alternatives with your provider. Extended half-life Factor IX products like Alprolix and Idelvion, or non-factor therapies like Alhemo (concizumab), may be appropriate bridge options.

Use medfinder to check availability. medfinder contacts treatment centers and specialty pharmacies on your behalf to find out which ones have Hemgenix in stock near you.

Why Hemgenix Availability Matters So Much

Before Hemgenix, adults with moderate-to-severe hemophilia B faced a lifetime of multiple Factor IX infusions per week — each costing between $550,000 and $750,000 annually. Hemgenix clinical trials showed a 54% reduction in annual bleed rates and allowed 94% of patients to discontinue prophylaxis entirely after a single dose. The potential to escape that treatment burden is enormous, which is why access delays have real health consequences.

For the most current update on the Hemgenix shortage, see our Hemgenix shortage update for 2026. And if you need help finding which treatment centers currently have Hemgenix in stock, medfinder can help you search

.